Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    The 5 Stocks Set To Dominate 2025

    May 28, 2025

    Top Graphene Stocks For 2025

    December 18, 2024

    Don’t Miss Out: These 5 Trump-Boosted Stocks Could Transform Your Portfolio!

    October 31, 2024
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Market MonitorsMarket Monitors
    • Home
    • Market News
      1. Company News
      2. Economic Updates
      3. Market Trends
      4. View All

      Adobe (ADBE) Surpasses Q3 2024 Expectations with Remarkable Earnings

      September 13, 2024

      DJT Stocks Tumble After Trump’s Debate with VP Harris

      September 12, 2024

      Sony Redefines Gaming: PS5 Pro Release Date Set for November (SNE)

      September 11, 2024

      DWAC Stock Soars 7% on Tight Trump vs. Harris Poll

      September 10, 2024

      Australia Targets Big Tech: New Misinformation Fines Could Exceed 5% of Annual Revenue

      September 13, 2024

      JPMorgan’s Latest Economic Forecast and Its Impact on the Fed’s Next Move

      September 12, 2024

      Will Today’s Inflation Report Change the Market Game?

      September 11, 2024

      Optimistic Outlook: Fed’s Soft Landing Strategy Might Be Working

      September 10, 2024

      Tech Renaissance Drives Market: Nvidia (NVDA), Apple (AAPL) and More In Spotlight

      September 13, 2024

      How Kamala Harris’s Debate Triumph (and $47M Fundraising) Can Impact Your Investments

      September 13, 2024

      Is NVDA’s Surge the Key to Understanding Today’s Market Trends?

      September 13, 2024

      MTV VMAs 2024 Embrace AI-Powered Shopping: Experience Fashion Like Never Before with PARA

      September 11, 2024

      Tech Renaissance Drives Market: Nvidia (NVDA), Apple (AAPL) and More In Spotlight

      September 13, 2024

      Australia Targets Big Tech: New Misinformation Fines Could Exceed 5% of Annual Revenue

      September 13, 2024

      How Kamala Harris’s Debate Triumph (and $47M Fundraising) Can Impact Your Investments

      September 13, 2024

      Adobe (ADBE) Surpasses Q3 2024 Expectations with Remarkable Earnings

      September 13, 2024
    • Stock Watchlists
      1. Best AI Stocks
      2. Best Income Stocks
      3. Best Value Stocks
      4. View All

      5 Must-Buy AI Stocks for Investor’s Long-Term Payoff & Potential 24% Gains

      August 20, 2024

      3 AI-Powered Healthcare Stocks to Make You Rich in 2023!

      August 20, 2024

      3 Explosive Stocks Chosen by Gemini AI for Massive Gains in 2024!

      August 19, 2024

      Top 3 AI Stocks That Could Deliver Massive Gains Over Nvidia

      August 19, 2024

      5 Mind-Blowing Reasons to Bet Big on GM Right Now!

      September 4, 2024

      5 High-Performing Utilities Stocks Poised for Big Gains—Don’t Miss Out!

      September 2, 2024

      Discover 7 Insurance Stocks Ready to Explode – Don’t Miss Out on These Market Winners

      August 27, 2024

      Top 6 Factors You Need to Consider Before Buying or Selling P&G Stock!

      August 26, 2024

      5 Stocks Set to Soar: Alcoa and Other Contrarian Opportunities

      September 4, 2024

      5 Reasons AstraZeneca Could Skyrocket: Is It the Ultimate GARP Investment?

      September 3, 2024

      4 Media Stocks Ready to Skyrocket: Expert Predictions and Price Targets Revealed

      September 2, 2024

      5 Must-Buy Stocks with High Operating Margins for Max Profit Potential

      September 2, 2024

      Don’t Miss Out: These 5 Trump-Boosted Stocks Could Transform Your Portfolio!

      October 31, 2024

      Ride the AI Boom: 5 Nuclear Stocks Primed for Explosive Growth – Up to 13.7% Gains!

      October 19, 2024

      Netflix Explodes Higher as Markets Soar to New Heights

      October 18, 2024

      Wall Street Notches Another Record Close, But Is The Writing on the Wall for Tech?

      October 17, 2024
    • Expert Analysis
    Market MonitorsMarket Monitors
    Home»Stock Watchlists»Growth Stocks»3 Gene Editing Stocks You Can’t Ignore If You Want Big Gains
    Growth Stocks

    3 Gene Editing Stocks You Can’t Ignore If You Want Big Gains

    These top-rated stocks are revolutionizing healthcare and promising enormous returns—don't miss out!
    Stock PickerBy Stock PickerJuly 7, 2024No Comments6 Mins Read
    Stocks
    StockPrice52 Week RangeMarketcapEPSDividend YieldChart (24H)SectorEmployeesLast Updated
    CRSP
    CRISPR Therapeutics AG
    CRSP
    $54.16
    4.93B5.400.00%
    Healthcare3933 hours ago
    VRTX
    Vertex Pharmaceuticals Incorpor
    VRTX
    $390.76
    100.19B14.070.00%
    Healthcare6,1003 hours ago
    SDGR
    Schrodinger, Inc.
    SDGR
    $19.40
    1.43B2.480.00%
    Healthcare8913 hours ago

    Profitable gene editing stocks make increasingly compelling investments as therapies get commercialized.

    Profitable Gene Editing Stocks - 3 Top-Rated Gene Editing Stocks Actually Making Money

    Gene editing utilizes enzymes to cut parts of the DNA strand, allowing for the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9. It is the most accurate, quickest, and least expensive method. Developments in the gene editing space have led to valuable stocks with strong ratings, which are worthy of investment.

    However, not all of these companies are profitable. Most of the gene editing stock opportunities lie in the promise of growth that will create future profitability, rather than current solid fundamentals. This can be problematic, as many companies never fulfill their potential. Therefore, it’s wiser to identify gene editing stocks that are either currently profitable or show the potential to become so soon.

    Let’s delve into three gene editing stocks that check these critical boxes.

    Editor’s Note: Analysis and insight for this article were originally sourced from our friends at InvestorPlace

    CRISPR Therapeutics (CRSP): Leading the Gene Editing Revolution

    CRISPR Therapeutics AG
    CRSP
    $54.16
    6%

    the CRISPR Therapeutics (CRSP) logo seen displayed on a smartphone

    CRISPR Therapeutics (NASDAQ:CRSP) is the original developer of the predominant gene editing technology. Their FDA-approved Casgevy is a game-changer for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.

    Why CRSP is a Strong Contender:

    The company’s investment in research and development and market expansion is ambitious, leading to a doubling of net losses in the first quarter, reaching $116.6 million. However, with over $2 billion in cash reserves, CRISPR Therapeutics is strongly positioned for the future.

    Priced at approximately $2.2 million per dose, Casgevy holds immense opportunity. Sickle cell disease affects more than 100,000 Americans and over 2 million people worldwide. This should give readers an idea of the immense opportunity ahead of the company.

    The company is expected to commercialize other CRISPR-Cas-9 based therapeutics moving forward, reinforcing its central role in the gene editing market. These factors underscore why CRSP stock is highly rated.

    Analyst Ratings for CRSP:

    Consensus Rating Average Price Target Current Price Potential Gain Number of Ratings
    Moderate Buy $79.13 $54.01 46.51% 17

    Summary: Analysts are predominantly optimistic about CRSP, with a consensus rating of Moderate Buy. For the next 12 months, the average price target stands at $79.13, representing a potential gain of 46.51% from the current price of $54.01. This indicates that, according to analysts, the stock has significant upside potential.

    Sources:

    1. Yahoo: Overview of CRSP Stock and Market Trends
      • Yahoo detailed the stock’s analyst ratings and provided updates on market performance.
    2. Zacks Investment Research: CRSP Price Targets
      • Zacks reported 22 short-term price targets with an average of $86.68, indicating a strong positive outlook.
    3. Wall Street Journal: CRISPR Therapeutics AG Analyst Estimates
      • This article provided an update on CRSP’s analyst ratings, stock prices, and earnings estimates.
    4. TipRanks: Crisp Therapeutics AG Stock Forecast
      • TipRanks analyzed 21 Buy Ratings, 6 Hold Ratings, and 1 Sell Rating, citing an average 12-month price target of $79.13.
    5. DigiTimes: CRISPR Therapeutics AG Price Targets
      • This source reported short-term price targets offered by 20 analysts with an average of $90.70.

    Vertex Pharmaceuticals (VRTX): Solid Fundamentals and Consistent Profits

    Vertex Pharmaceuticals Incorpor
    VRTX
    $390.76
    0%

    Red blood cells.

    Vertex Pharmaceuticals (NASDAQ:VRTX) is currently rated as a buy by analysts.

    Why VRTX is a Must-Watch:

    Together with CRISPR Therapeutics, Vertex launched gene therapies for inherited blood disorders, leading to strong fundamentals. Vertex received FDA approval for Casgevy to treat rare inherited blood disorders earlier this year, succeeding a December approval for sickle cell disease. Expectations for Casgevy’s peak sales reach $400 million annually.

    Vertex’s strong fundamental performance is noteworthy. The company has consistently produced net profits over the past five years and beyond. This blend of strong fundamentals and the ability to bring gene editing to commercial viability make Vertex Pharmaceuticals a strong investment.

    Analyst Ratings for VRTX:

    Consensus Rating Average Price Target Current Price Potential Gain Number of Ratings
    Moderate Buy $467.00 $463.42 0.83% 17 – 5 – 2

    Summary: Analysts have a Moderate Buy consensus rating for Vertex Pharmaceuticals (VRTX). The average price target is $467.00, which is slightly higher than the current stock price of $463.42. This indicates a potential gain of approximately 0.83% if the stock price reaches the average target.

    Sources:

    1. Investing.com: Detailed forecasting and price targets based on consensus analyst predictions.
    2. Nasdaq: Analyst research and ratings consensus summary provides insights into stock price targets.
    3. TipRanks: Detailed analysis of analyst ratings, forecasts, and recommendations for stocks, including VRTX.
    4. Yahoo Finance: Historical stock prices, including earnings and revenue forecasts, which help analyze analyst outlook.

    Schrödinger (SDGR): Innovating with AI to Fuel Big Gains

    Schrodinger, Inc.
    SDGR
    $19.40
    3%

    Gene editing stocks: a concept image of a hand holding a pair of tweezers that is pulling a section off of a dna strand

    Schrödinger (NASDAQ:SDGR) has harnessed the power of AI in its business, setting itself apart in the gene editing landscape.

    Why SDGR Should Be On Your List:

    Schrödinger is a software and drug discovery firm that has developed a physics-based computational platform for discovering novel molecules. This platform not only builds its own clinical programs but is also sold to other pharmaceutical firms, creating multiple revenue streams.

    Schrödinger’s software is widely applicable across the gene editing and pharma sectors. While the company doesn’t disclose sales at the company level, it’s highly likely that Schrödinger is collaborating with multiple gene editing firms.

    The stock is highly regarded by analysts with consensus estimates forecasting significant growth, potentially doubling in value. Given its innovative approach and broad applicability in the sector, Schrödinger remains a highly touted investment.

    Analyst Ratings for SDGR:

    Consensus Rating Average Price Target Current Price Potential Gain Number of Ratings
    Moderate Buy $35.17 $19.34 81.85% 6

    Summary: Analysts for SDGR have a consensus rating of Moderate Buy, reflecting a mix of “buy,” “hold,” and “sell” recommendations. The average 12-month price target stands at $35.17, indicating an impressive potential gain of 81.85% from the current price of $19.34.

    Sources:

    1. TechCrunch: Discusses Yahoo’s brand portfolio and provides options for users to manage their privacy settings, including a link to privacy policies and cookie policies.
    2. Nasdaq Analyst Research: Provides analyst research for SDGR, including ratings consensus and stock price targets.
    3. TipRanks: Contains analyst forecasts and price target predictions for SDGR, along with a breakdown of the overall industry performance compared to SDGR’s historical performance.
    4. Morningstar: Displays historical stock performance data, including total returns for SDGR.
    5. WSJ: Offers a summary of SDGR’s analyst estimates and ratings, including updates on stock price targets.
    About Us
    About Us

    We're your inside source for the world's most profitable stock and investing ideas. We cut through the noise to bring you the high-conviction, market-moving information that can take your portfolio to the next level.

    Join thousands of individual investors who rely on Market Monitors to stay ahead of the game.

    Sign up for our free newsletter for our latest stock pick every morning before the market opens.

    Email Us: [email protected]

    Facebook X (Twitter) YouTube LinkedIn
    Our Picks

    The 5 Stocks Set To Dominate 2025

    May 28, 2025

    Top Graphene Stocks For 2025

    December 18, 2024

    Don’t Miss Out: These 5 Trump-Boosted Stocks Could Transform Your Portfolio!

    October 31, 2024
    Most Popular

    French Regulators Target Nvidia (NVDA): Could the AI Giant Be Broken Up?

    July 2, 2024

    Tesla (TSLA) Stumbles Amid Recalls, While Polestar (PSNY) Surges on New Launches

    July 2, 2024

    Investors Backing Off Eli Lilly (LLY): What’s Driving the Market Shift?

    July 2, 2024

    Type above and press Enter to search. Press Esc to cancel.